Primary study · included by 1 review

Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial.

Mallick 2025 · Mallick Ujjal, Newbold Kate, Beasley Matthew, et al. · Lancet (London, England) · 2025

Included by

Reassessing Radioactive Iodine Use After Thyroidectomy in Low-Risk Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis.

Non-Cochrane · intervention · 2026 · cited as Mallick 2025 · Table 1; Fig. 3-8

Outcome this study informs	Pooled effect	Evidence	Certainty
Recurrence Radioactive iodine (RAI) ablation after total thyroidectomy vs No RAI (total thyroidectomy alone)	OR 0.66 [0.41, 1.08]	7 studies · 4101 participants	GRADE not reported
5-year recurrence-free survival Radioactive iodine (RAI) ablation after total thyroidectomy vs No RAI (total thyroidectomy alone) · 5 years	OR 4.70 [1.39, 15.97]	3 studies · 2493 participants	GRADE not reported
Elevated thyroglobulin antibodies Radioactive iodine (RAI) ablation after total thyroidectomy vs No RAI (total thyroidectomy alone)	OR 0.91 [0.38, 2.16]	2 studies · 1280 participants	GRADE not reported
Xerostomia (adverse effect) Radioactive iodine (RAI) ablation after total thyroidectomy vs No RAI (total thyroidectomy alone)	OR 5.63 [0.05, 667.24]	2 studies · 748 participants	GRADE not reported
5-year recurrence-free survival Radioactive iodine (RAI) ablation after total thyroidectomy vs No RAI (total thyroidectomy alone) · 5 years	OR 2.47 [0.63, 9.62]	4 studies · 2997 participants	GRADE not reported
Dysphonia (adverse effect) Radioactive iodine (RAI) ablation after total thyroidectomy vs No RAI (total thyroidectomy alone)	OR 0.96 [0.53, 1.72]	2 studies · 748 participants	GRADE not reported

1 including review in total.